NCT06099990View on ClinicalTrials.gov

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

660

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets

dalpiciclib+ abiraterone+ prednisone

DRUG

placebo; abiraterone acetate tablets; prednisone tablets

placebo+abirarerone+prenisone

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06099990 - Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) | Biotech Hunter | Biotech Hunter